Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.
Standard of care treatment of dogs with multicentric lymphoma includes combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP); however, owners may be hesitant to commit the resources necessary to complete a lengthy, multi-drug protocol. One hundred thirty-four client-owned dogs with multicentric lymphoma were treated with a 15-week CHOP chemotherapy protocol. The overall response rate was 98% with 104 dogs experiencing a complete response (CR). The median progression-free survival (PFS) time for all dogs was 176 days, and the median disease-specific overall survival time was 311 days. Prognostic factors identified on multivariate analysis as significant for PFS included substage, immunophenotype, hospitalization for adverse events, need for dose reduction, presence of neutrophilia at diagnosis, presence of anemia and experiencing a CR as best response to therapy. In conclusion, this protocol may be a viable alternative to CHOP protocols using a larger number of treatments.
Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.
K
K
Curran
Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.|Cell and Molecular Biology Graduate Program, Colorado State University, Fort Collins, CO, USA.|Developmental Therapeutics Program, Comprehensive Cancer Center, University of Colorado, Aurora, CO, USA.
D H
DH
Thamm
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D003120:Colorado; D003520:Cyclophosphamide / Q000494:pharmacology; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000494:pharmacology; D005260:Female; D016130:Immunophenotyping; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D015999:Multivariate Analysis; D011239:Prednisolone; D011241:Prednisone; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000494:pharmacology
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D011241:Prednisone
chemotherapy; dog; lymphoma; lymphosarcoma; small animal